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However, slow coronary flow (SCF), which was first described by Tambe et al, is an angiographic finding characterized by slow antegrade progression of contrast agent to the distal branch of a coronary artery in the absence of obstructive coronary artery disease. 8 Although, at present, the exact underlying pathophysiological mechanisms of this unique angiographic phenomenon are not fully understood, several mechanisms have been proposed for the etiology of SCF, including endothelial activation and inflammation. 9 Clinically, SCF was reported to be associated with angina, acute myocardial infarction 10 and signs of ischemia during stress tests. 11, 12 Moreover, on a recent report associated with SCF and with scintigraphic signs of ischemia in the related coronary territory, a worse cardiovascular prognosis was demonstrated. 13 It was suggested that SCF without evident cause might represent a new entity of coronary heart disease. 14 In the current study, we aimed to evaluate coronary blood flow in patients with COPD having angiographically proven normal coronary arteries by means of Thrombolysis In Myocardial Infarction (TIMI) frame count. Secondly, we aimed to evaluate associates of coronary flow in COPD patients.
Methods

Study Groups
Patients A total of 85 patients with moderate to severe COPD [forced expiratory volume 1 s (FEV1) <70% of pre-
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dicted, FEV1/forced vital capacity (FVC) <70% and reversibility with bronchodilators less than 10% of the predicted value] who underwent diagnostic coronary angiography in Turkiye Yuksek Ihtisas Hospital Cardiology Clinic and found to have normal epicardial coronary angiogram constituted the patient group. The diagnosis of COPD was made according to criteria by the American Thoracic Society standards. 15 All patients with COPD had a history of smoking (50 (59%) of them ex-smokers and the remaining 35 (41%) were current smokers) and were clinically stable and free of exacerbation history for at least 4 weeks before angiography. Drug treatment regimens were inhaled anticholinergics (n: 26), inhaled β-agonists (n: 18) or both (n: 36). Five of the COPD patients were not taking any bronchodilator drug at the commencement of the study. None of the patients were receiving long term oxygen therapy or corticosteroid treatment and bronchodilator treatments were ceased at least 24 h before the angiography.
Control Group The control group was made up of 39 ageand sex-matched patients having normal coronary angiogram, normal spirometry test results and no history of infection in the preceding 1 month.
All study participants were referred to coronary angiography due to the presence of angina or angina-like chest pain. Patients admitted with acute coronary syndrome, patients found to have structural heart disease on echocardiography, patients with left ventricular wall motion abnormality assessed by left ventriculography, vasospastic angina, documented arrhythmia, renal and hepatic dysfunction, any history of collagen vascular disease and malignancy were excluded from the study. Patients with pulmonary disorders at present or in the past other than COPD were excluded as well. All vasoactive medication were discontinued 24 h before the angiography.
All patients gave written informed consent to participate in the study, which was approved by the local ethics committee of the hospital.
Pulmonary function tests were performed by using MIR Spirolab II spirometry (Medical International Research, Rome, Italy). FVC and FEVI were measured and results were given as percent of predicted values calculated from the reference values reported by the European Community for Coal and Steel. 16 The severity of COPD was determined by the Global Initiative on Obstructive Lung Disease (GOLD) classification. 17 Stage I (mild): FEV1/FVC <70% and FEV1 ≥80% predicted. With or without chronic symptoms (cough, sputum production). Stage II (moderate): FEV1/FVC <70% and 50% ≤FEV1<80% predicted. With or without chronic symptoms (cough, sputum production). Stage III (severe): FEV1/FVC <70% and 30%≤FEV1<50% predicted. With or without chronic symptoms (cough, sputum production). Stage IV (very severe): FEV1/FVC <70% and FEV1 <30% predicted or FEV1 <50% predicted plus chronic respiratory failure. Patients might have very severe (Stage IV) COPD even if the FEV1 is >30% predicted, whenever this complication is present.
Laboratory Measurements White blood cell (WBC) counts, platelet counts, fibrinogen concentrations and biochemical measurements including cholesterol and tryglyceride concentrations were determined by standard laboratory methods. The high sensitive C-reactive protein (hsCRP) was measured by immunonephelometry (Immage Immunochemistry system; Beckman Coulter, USA).
Coronary Angiography and Determination of SCF
In all study participiants, coronary angiography was performed by femoral artery approach using the Judkins technique. Coronary arteries were visualized in right and left oblique planes with cranial and caudal angulations and recorded at a film rate of 30 frame/s. During the coronary angiography and left ventriculography iopromide (Ultravist 370, Schering AG, Berlin) was used as the contrast agent in all patients.
For the objective quantification of the coronary flow, 2 independent observers, who were blinded to the clinical and laboratory data of the study participants' assessed the coronary flow in coronary arteries using the TIMI frame count method, described by Gibson et al. 18 In this method, the number of cine frames recorded at 30 frames/s required for the contrast to first reach standard distal coronary landmarks in left anterior descending (LAD), circumflex (CX) and right coronary arteries (RCA) were measured. Predefined distal landmarks are the distal bifurcation for the LAD, commonly referred as the 'pitchfork' or 'whale's tail', the distal bifurcation of the segment with the longest total distance for the CX, and the first branch of the posterolateral artery for the RCA. As the LAD coronary artery is usually longer than the other major coronary arteries, the TIMI frame count for LAD was divided by 1.7 to obtain the corrected TIMI frame count. 18 The mean TIMI frame count for each patient and control participant was calculated by dividing the sum of the TIMI frame counts of LAD, CX and RCA by 3.
Statistical Analysis
Continuous data were presented as means ± standard deviation. Differences in continuous variables between the groups were determined by Student's t-test or Mann Whitney U-test for variables with or without normal distribution, respectively. Categorical variables were presented as percentages and compared with chi-squared test or Fisher's exact test. The Spearman correlation coefficient was calculated to evaluate the association between 2 continuous variables. In order to determine independent associates of SCF we performed stepwise linear regression analysis, including mean TIMI frame count as dependent and age, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride concentrations, fibrinogen, hsCRP, smoked cigarettes as packet year, FEV1% as independent variables. To rule out the effect of smoking index on TIMI frame count in the COPD group covariance analysis was performed. P<0.05 values were accepted as statistically significant and confidence intervals (CI) computed were 95%. All analyses were performed using SPSS 11.5 (SPSS Inc, Chicago, Illinois, USA).
Results
The baseline demographic, clinical and pulmonary function characteristics of the COPD patients and control group participants are summarized in Table 1 . According to the GOLD classification, 32 patients had stage II (moderate), 45 patients had stage III (severe), and 8 patients had stage IV (very severe) COPD in COPD group. The 2 groups were similar in terms of age, gender and body mass index (BMI). Although heart rate and systolic blood pressure was higher in COPD patients than in the control group participants, it was not statistically significant (P>0.05). The patients with COPD did not differ from the control group participants with regard to major cardiovascular risk factors such as hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking and family history of premature coronary artery disease (all P> SELCUK H et al. 
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0.05). Although there was no significant difference between the 2 groups with regard to current smoking status, the patients in COPD group had significantly higher total smoked packet/year than the participants in the control group.
When pulmonary function test results were compared, as expected, the patients in the COPD group had significantly lower FEV1% (46±14 vs 109±11) and FVC% (63±11 vs 96±9) than the control group participants.
The TIMI frame count of the COPD group was significantly higher than that of the control group for all 3 major coronary arteries: LAD (corrected) (37±13 vs 20±4, P<0.001); RCA (32±14 vs 21±4, P<0.001); and left CX (34±12 vs 20± 5, P<0.001) (Figure) . The COPD group, when compared to the control group participants, had mean TIMI frame count significantly higher (34±11 vs 20±3, P<0.001).
While the 2 groups did not differ in terms of circulating concentrations of total WBC and platelet count (all P>0.05), fibrinogen concentrations was found to be higher in patients with COPD when compared to participants in the control group (P: 0.044) ( Table 2 ). In addition, patients with COPD, plasma hsCRP concentrations were found to be significantly higher than those of control group participants (1.04± 1.20 mg/dl vs 0.48±0.49 mg/dl, P: 0.022) ( Table 2) .
However, the groups were similar in terms of serum lipid profiles. There were no significant differences in the total, LDL and HDL-cholesterol concentrations as well as triglyceride concentrations between the 2 groups (all P>0.05) ( Table 2) .
To find out if there is a gender difference among the variables in the COPD group we compared COPD group patients according to sex. Male and female patients were similiar in terms of age (58.2±9.9 vs 58.7±9.3, P: 0.845), BMI (27.2±4.6 vs 28.1±4.1, P: 0.387), major cardiovascular risk factors, total smoked packet/year (28±13 vs 28±15, P: 0.808), fibrinogen concentrations (327±139 mg/dl vs 340±113 mg/dl, P: 0.646), hsCRP concentrations (0.97±1.16 mg/dl vs 1.15±1.28 mg/dl, P: 0.492) in the COPD group. We did not detect any significant difference in terms of TIMI frame counts of individual arteries (for LAD 37±14 vs 37±13, for CX 35±13 vs 33±11, for RCA 34±16 vs 28±10, P>0.05 for all, males vs females, respectively). There were no significant difference in terms of FVC% (63±12 vs 62±11, P: 0.794) and FEV1% (45±14 vs 47±13, P: 0.638 for males and females, respectively) Correlation Analysis Patients in the COPD group, as shown in Table 3 , hsCRP, fibrinogen concentrations and total smoked packet/years, were found to be positively correlated with TIMI frame count for each coronary artery as well as with the mean TIMI frame count. However, a significant negative correlation was detected between FEV1% and the TIMI frame count for each coronary artery (for LAD, r: -0.512, P<0.001; for CX, r: -0.413, P<0.001; for RCA, r: -0.540, P<0.001; for mean, r: -0.585, P<0.001). There was also a significant negative correlation between FVC% and the TIMI frame count for each coronary artery (for LAD, r: -0.336, P: 0.002; for CX, r: -0.322, P: 0.003; for RCA, r: -0.285, P: 0.008; for mean, r: -0.373, P: 0.001). However, there was no correlation between individual and mean TIMI frame counts and age, BMI, total cholesterol, LDL-cholesterol and triglyceride concentrations (all P>0.05).
To find out if there is any difference associated with gender among correlates of coronary flow in COPD group we reperformed the correlation analysis separating the group according to sex. As a result; while hsCRP, fibrinogen concentrations and total smoked packet/years were found to be positive, FEV1% appeared as a negative correlate of TIMI frame count for each coronary artery as well as with the mean 
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TIMI frame count for both sexes. However, while FVC% was not a significant correlate of coronary flow for males, it was a significant negative correlate of the TIMI frame count for each coronary artery as well as with the mean TIMI frame count (for LAD, r: -0.589, P<0.001; for LCX, r: -0.570, P<0.001; for RCA, r: -0.431, P: 0.011; for mean r: -0.626, P: <0.001) for females. To find out independent associates of coronary flow in COPD patients, linear regression analysis was performed using mean TIMI frame count as the dependent and age, BMI, cigarette smoking, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride and hsCRP, fibrinogen, WBC counts, FVC%, FEV1% as independent variables. Among these variables, hsCRP (β: 0.312, t: 3.637, 95%CI: 1.308-4.479, P: 0.001), fibrinogen concentrations (β: 0.197, t: 2.137, 95%CI: 0.115-3.313, P: 0.036), total smoked cigarette packets/year (β: 0.176, t: 2.031, 95%CI: 0.003-0.281, P: 0.046) and FEV1% (β: -0.287, t: -2.888, 95%CI: -0.393 to -0.072, P: 0.005) were found to be associated independently with SCF.
We performed covariance analysis to rule out the effect of smoking index on TIMI frame count in COPD group. As a result after ruling out the effect of smoking index on TIMI frame count, mean TFC was significantly longer in the COPD group than the control group (33±1 vs 20±2, P<0.001 in COPD and control groups, respectively).
Discussion
With this report, being the first time reported in the literature to the best of our knowledge, we have shown the association of moderate to severe COPD with SCF in COPD patients who underwent cardiac catheterization for evaluation of chest pain and found to have normal epicardial coronary angiogram. SCF might be one part of the spectrum of cardiovascular diseases associated with COPD. Moreover, the moderate inverse correlation we observed between FEV1 and coronary flow suggested a close relationship between the severity of COPD and impaired coronary flow. Accordingly in previous reports, association of reduced FEV1, which is the defining feature of COPD, with increased risk of atherosclerosis and increased risk of cardiovascular complications were reported. 3, 19 Moreover, it has been shown that for every 10% decrease in FEV1, all-cause mortality increased by 14%, cardiovascular mortality increased by 28% and non-fatal coronary events increased by almost 20% after adjustments for relevant confounders including age and smoking status. [20] [21] [22] One of the potential mechanisms suggested to explain risk of poor cardiovascular outcomes in COPD patients, is the presence of persistent low-grade inflammation. 6, 23 There is growing evidence that COPD is a systemic and inflammatory disorder associated with both local lung and systemic inflammation. 6, 23 Systemic inflammation is related not only to accelerated progression of COPD but also to cardiovascular disorders including ischemic heart disease. 7 The precise pathopysiological mechanisms underlying the SCF phenomenon are not fully known but several hypothesis including a form of early phase of atherosclerosis, 24 small vessel dysfunction, 25 endothelial dysfunction leading to imbalance between vasoconstrictor and vasodilatory factors, 26 platelet dysfunction 27 and recently inflammation 9 have been suggested.
Our findings of significantly higher concentrations of hsCRP and fibrinogen in patients with COPD compared to those with normal coronary flow are in accordance with previous reports implying inflammatory nature of COPD. Taking into account detection of SCF in COPD patients in our study group, inflammation might be the mechanism coupling COPD to SCF. Moreover, positive correlation we detected between hsCRP and TIMI frame count in the COPD group further supports inflammation as the underlying mechanism of SCF. Accordingly, there are reports in the literature linking the inflammation with SCF. Turhan et al reported higher levels of intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin in patients with SCF suggesting that these increased concentrations of inflammatory cytokines might be an indicator of endothelial activation and inflammation and are likely to be in the causal pathway leading to SCF. 9 Moreover, in patients with SCF, elevated concentrations of IL-6 and hsCRP, was reported compared to individuals with normal coronary flow. 28 In COPD patients, the nidus for the low-grade systemic inflammation is likely the airways. There is evidence to show that small airways of COPD patients are persistently inflamed and that the intensity of the inflammatory process correlates with the severity of COPD. 29 Previously it was shown that severe airflow obstruction (defined as FEV1 <50% of predicted) increased the probability of having elevated CRP in the systemic circulation by 2.18-fold compared with normal lung function. 30 Moreover Cirillo et al showed an inverse association between FEV1 and serum CRP. 31 Accordingly in the present study we have detected moderate negative correlation between CRP and FEV1% concentrations in the COPD group. Our findings indicate that airflow obstruction is an important risk factor for SCF. Inflammation might be one of the possible linkage between reduced FEV1% and SCF.
The origin of the systemic inflammation present in patients with COPD remains poorly understood and several independent pathways might be involved. 4 As smoking causes many important extrapulmonary effects, tobacco smoke alone might contribute significantly to systemic inflammation in COPD. 4 The correlation we observed between the total amount of cigarettes smoked and TIMI frame counts of individual coronary vessels suggested to us that smoking was the initiating agent of such an inflammatory state in our COPD group. Once COPD is established, airway inflammation persists even after many years of smoking cessation. Smoking and other environmental irritants might activate alveolar macrophages and bronchial epithelial cells in the airways of genetically susceptible individuals. These cells once activated can also produce IL-6 and IL-1B, which might stimulate hepatocytes to synthesize acute phase proteins such as CRP and fibrinogen. 30, 32 When released into the systemic circulation CRP has the capability of amplifying the inflammatory cascade. These molecules in conjunction with traditional risk factors such as hypertension, hypercholesterolemia, and advanced glycation end products, promote atherogenesis and cardiovascular disease. 30 Its production can be tonically increased by chronic low-grade inflammation and in laboratory experiments it has been shown that CRP actively participates in the development of a pro-inflammatory and pro-atherosclerotic phenotype. 30 For other acute phase proteins, such as fibrinogen, the same fact applies as well.
Previously, association of SCF with endothelial dysfunction was reported. 26, 33, 34 In COPD presence of endothelial dysfunction was also demonstrated. 35 Therefore, endothelial dysfunction might represent another link between COPD and SCF, whether it was initiated by smoking, inflammation or COPD itself.
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Although at present the direct clinical consequences of this unique angiographic phenomenon are not fully studied, there are reports against it being just an innocent angiographic finding. Increasing evidence supports the hypothesis that the slow coronary phenomenon is a clinical entity that might be related with important clinical outcomes. A recent report on patients with syndrome X conducted by Fragasso et al, showed that the patients exhibiting SCF had a significant myocardial perfusion defect in the regions served by the coronary artery that showed slow flow. 13 More importantly in the same study, it was shown that the patients with SCF had worse cardiac prognosis than those without SCF during a long follow-up period. This report was important as it showed the association of SCF with clinical sequela directly and this point needs further prospectively designed follow up studies.
Our findings provide additional support for the hypothesis that endothelial activation and inflammation might play an important role in the pathogenesis of SCF.
Conclusion
Regardless of the precise mechanisms involved, COPD patients are at an increased risk of cardiovascular events. With the current study we have shown the presence of impaired coronary flow documented by TIMI frame count method in COPD patients. An increased TIMI frame count can be regarded as an index of harmful effects of COPD on the coronary circulation. SCF might be one part of the spectrum of cardiovascular diseases associated with COPD. Although coronary angiograms show the normal presence of SCF, it might highlight the impaired microvascular endothelial function and vasomotion in COPD patients. Further similarly designed clinical studies, perhaps utilizing more direct means of coronary flow measurement, such as intravascular ultrasonography, with sufficient follow up period and utilizing cardiovascular endpoints are needed for clarification of direct clinical correlates of our finding of SCF in COPD patients.
Study Limitations
In addition to a relatively small number of patients, the present study is limited by its cross-sectional design that makes it impossible to find out a causal relationship between COPD and SCF. Another important limitation of our study was that the most of the patients in both groups was on vasoactive medication that might impact coronary flow. In addition, although the BMI of our study group participants is relatively higher than the controls, we did not specifically investigate obstructive sleep apnea, which might be a significant comorbidity having potential to influence coronary flow. Obstructive sleep apnea is a highly prevalent clinical condition in patients with cardiovascular disease and associated with multiple metabolic abnormalities including obesity, insulin resistance and dyslipidemia. Obstructive sleep apnea has been reported to be associated with various forms of cardiac diseases, such as coronary artery disease, left ventricular diastolic function and atrial fibrillation. [36] [37] [38] Sympathetic activation, systemic inflammation, endothelial dysfunction and oxidative stress have been shown to be related with obstructive sleep apnea, which are also factors believed to be underlying mechanisms for SCF. 39 
